NURIX THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NURIX THERAPEUTICS, INC. (NRIX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.40 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-05-31 was $11.40M, a 9.76% increase year-over-year.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-02-28 was $9.40M, a 7.77% increase year-over-year.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-08-31 was $9.78M, a 11.57% increase year-over-year.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-05-31 was $10.39M, a 17.44% increase year-over-year.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.98M, a 11.91% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $33.94M, a 0.58% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $33.75M, a 19.67% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $28.20M, a 78.48% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-05-31 | $11.40M 10-Q · filed 2026-07-09 | $20.81M derived: sum of 2 quarters · filed 2026-07-09 | ||
| 2026-02-28 | $9.40M 10-Q · filed 2026-07-09 | |||
| 2025-11-30 | $37.98M 10-K · filed 2026-01-28 | |||
| 2025-08-31 | $9.78M 10-Q · filed 2025-10-09 | $20.17M derived: sum of 2 quarters · filed 2026-07-09 | $28.89M derived: sum of 3 quarters · filed 2026-07-09 | |
| 2025-05-31 | $10.39M 10-Q · filed 2026-07-09 | $19.12M derived: sum of 2 quarters · filed 2026-07-09 | ||
| 2025-02-28 | $8.73M 10-Q · filed 2026-07-09 | |||
| 2024-11-30 | $33.94M 10-K · filed 2026-01-28 | |||
| 2024-08-31 | $8.76M 10-Q · filed 2025-10-09 | $17.61M derived: sum of 2 quarters · filed 2025-10-09 | $25.43M derived: sum of 3 quarters · filed 2025-10-09 | |
| 2024-05-31 | $8.85M 10-Q · filed 2025-10-09 | $16.67M derived: sum of 2 quarters · filed 2025-10-09 | ||
| 2024-02-29 | $7.82M 10-Q · filed 2025-10-09 | |||
| 2023-11-30 | $33.75M 10-K · filed 2026-01-28 | |||
| 2023-08-31 | $8.47M 10-Q · filed 2024-10-11 | $17.22M derived: sum of 2 quarters · filed 2024-10-11 | $25.72M derived: sum of 3 quarters · filed 2024-10-11 | |
| 2023-05-31 | $8.75M 10-Q · filed 2024-10-11 | $17.25M derived: sum of 2 quarters · filed 2024-10-11 | ||
| 2023-02-28 | $8.51M 10-Q · filed 2024-10-11 | |||
| 2022-11-30 | $28.20M 10-K · filed 2025-01-28 | |||
| 2022-08-31 | $6.99M 10-Q · filed 2023-10-12 | $13.76M derived: sum of 2 quarters · filed 2023-10-12 | $19.83M derived: sum of 3 quarters · filed 2023-10-12 | |
| 2022-05-31 | $6.78M 10-Q · filed 2023-10-12 | $12.85M derived: sum of 2 quarters · filed 2023-10-12 | ||
| 2022-02-28 | $6.07M 10-Q · filed 2023-10-12 | |||
| 2021-11-30 | $15.80M 10-K · filed 2023-02-09 | |||
| 2021-08-31 | $4.31M 10-Q · filed 2022-10-06 | $8.26M derived: sum of 2 quarters · filed 2022-10-06 | $10.96M derived: sum of 3 quarters · filed 2022-10-06 | |
| 2021-05-31 | $3.94M 10-Q · filed 2022-10-06 | $6.64M derived: sum of 2 quarters · filed 2022-10-06 | ||
| 2021-02-28 | $2.70M 10-Q · filed 2022-10-06 | |||
| 2020-11-30 | $4.30M 10-K · filed 2022-01-28 | |||
| 2020-08-31 | $1.11M 10-Q · filed 2021-10-14 | $1.59M derived: sum of 2 quarters · filed 2021-10-14 | $1.76M derived: sum of 3 quarters · filed 2021-10-14 | |
| 2020-05-31 | $474.00K 10-Q · filed 2021-10-14 | $650.00K derived: sum of 2 quarters · filed 2021-10-14 | ||
| 2020-02-29 | $176.00K 10-Q · filed 2021-10-14 | |||
| 2019-11-30 | $510.00K 10-K · filed 2022-01-28 | |||
| 2019-08-31 | $136.00K 10-Q · filed 2020-10-14 | $241.00K derived: sum of 2 quarters · filed 2020-10-14 | $343.00K derived: sum of 3 quarters · filed 2020-10-14 | |
| 2019-05-31 | $105.00K 10-Q · filed 2020-10-14 | $207.00K derived: sum of 2 quarters · filed 2020-10-14 | ||
| 2019-02-28 | $102.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |